Alexandra Calmy

Summary

Publications

  1. ncbi request reprint Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy
    Alexandra Calmy
    Division of aInfectious Diseases, Hopital Cantonal Universitaire, Geneva, Switzerland
    AIDS 17:770-2. 2003
  2. doi request reprint Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon
    Christian Laurent
    Institut de Recherche pour le Developpement, UMR 145 IRD University of Montpellier 1, Montpellier, France
    AIDS Res Hum Retroviruses 24:393-9. 2008
  3. pmc Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings
    Alexandra Calmy
    HIV Unit, Geneva University Hospital, Geneva, Switzerland
    BMC Infect Dis 12:147. 2012
  4. ncbi request reprint [News in HIV/AIDS therapy]
    A Calmy
    Service des Maladies Infectieuses, HUG, 1211 Geneve
    Rev Med Suisse 8:130-4. 2012
  5. ncbi request reprint Clinical update: adverse effects of antiretroviral therapy
    Alexandra Calmy
    St Vincent s Hospital, Sydney 2010, NSW, Australia
    Lancet 370:12-4. 2007
  6. doi request reprint Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study
    Alexandra Calmy
    HIV, Immunology and Infectious Diseases Unit, University of New South Wales, Sydney, Australia
    J Infect Dis 200:1746-54. 2009
  7. doi request reprint Safety and efficacy of once-daily nevirapine dosing: a multicohort study
    Alexandra Calmy
    Division of Infectious Disease HIV unit, University Hospital Geneva, Geneva, Switzerland
    Antivir Ther 14:931-8. 2009
  8. doi request reprint No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial
    A Calmy
    HIV, Immunology and Infectious Diseases Unit, Centre for Applied Medical Research, St Vincent s Hospital, Sydney, Australia
    HIV Med 11:493-501. 2010
  9. doi request reprint Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy
    A Calmy
    St Vincent s Hospital, Sydney, Australia
    HIV Med 9:101-10. 2008
  10. ncbi request reprint HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial
    Alexandra Calmy
    HIV Unit, Geneva University Hospital, 15 rue Micheli Du Crest, Geneva 1205, Switzerland
    AIDS 23:929-39. 2009

Detail Information

Publications59

  1. ncbi request reprint Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy
    Alexandra Calmy
    Division of aInfectious Diseases, Hopital Cantonal Universitaire, Geneva, Switzerland
    AIDS 17:770-2. 2003
  2. doi request reprint Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon
    Christian Laurent
    Institut de Recherche pour le Developpement, UMR 145 IRD University of Montpellier 1, Montpellier, France
    AIDS Res Hum Retroviruses 24:393-9. 2008
    ..In view of stavudine toxicity, these results support recommendations calling for a gradual switch from stavudine- to zidovudine-based regimens...
  3. pmc Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings
    Alexandra Calmy
    HIV Unit, Geneva University Hospital, Geneva, Switzerland
    BMC Infect Dis 12:147. 2012
    ..We assessed the impact of on-going HIV-RNA replication on CD4 cell count slopes in patients treated with a first-line combination ART...
  4. ncbi request reprint [News in HIV/AIDS therapy]
    A Calmy
    Service des Maladies Infectieuses, HUG, 1211 Geneve
    Rev Med Suisse 8:130-4. 2012
    ..Finally, the first phase I clinical trials of gene therapy are being presented later this year, allowing the hope of HIV cure...
  5. ncbi request reprint Clinical update: adverse effects of antiretroviral therapy
    Alexandra Calmy
    St Vincent s Hospital, Sydney 2010, NSW, Australia
    Lancet 370:12-4. 2007
  6. doi request reprint Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study
    Alexandra Calmy
    HIV, Immunology and Infectious Diseases Unit, University of New South Wales, Sydney, Australia
    J Infect Dis 200:1746-54. 2009
    ..The role of proximal renal tubular dysfunction (PRTD) and alterations in bone metabolism in HIV-related low BMD are incompletely understood...
  7. doi request reprint Safety and efficacy of once-daily nevirapine dosing: a multicohort study
    Alexandra Calmy
    Division of Infectious Disease HIV unit, University Hospital Geneva, Geneva, Switzerland
    Antivir Ther 14:931-8. 2009
    ..Nevirapine (NVP) is often prescribed once daily in clinical practice in combination with a once daily nucleoside backbone. We investigated the relationship of NVP dosing with safety and efficacy...
  8. doi request reprint No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial
    A Calmy
    HIV, Immunology and Infectious Diseases Unit, Centre for Applied Medical Research, St Vincent s Hospital, Sydney, Australia
    HIV Med 11:493-501. 2010
    ..Today, most patients with lipoatrophy receive non-tNRTI-based ART; the effect of uridine in such patients is unknown...
  9. doi request reprint Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy
    A Calmy
    St Vincent s Hospital, Sydney, Australia
    HIV Med 9:101-10. 2008
    ..We investigated whether metabolic and body composition parameters could predict the development of LD over 2 years in adults initiating antiretroviral therapy (ART)...
  10. ncbi request reprint HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial
    Alexandra Calmy
    HIV Unit, Geneva University Hospital, 15 rue Micheli Du Crest, Geneva 1205, Switzerland
    AIDS 23:929-39. 2009
    ..We investigated whether HIV replication modified the levels of these proteins in a combination antiretroviral therapy (cART) interruption trial...
  11. ncbi request reprint HIV viral load monitoring in resource-limited regions: optional or necessary?
    Alexandra Calmy
    Medecins Sans Frontieres, Access to Medicines Campaign, Geneva, 1211, Switzerland
    Clin Infect Dis 44:128-34. 2007
    ..Rather than considering viral load data to be an unaffordable luxury, efforts should be made to ensure that viral load testing becomes affordable, simple, and easy to use in resource-limited settings...
  12. doi request reprint Association of alcohol consumption and HIV surrogate markers in participants of the swiss HIV cohort study
    Anna Conen
    Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital Aarau, Aarau, Switzerland Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland Clinic for Infectious Diseases, University Hospital Berne, University of Berne, Berne, Switzerland Division of Infectious Diseases and Hospital Epidemiology, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland Division of Infectious Diseases and Hospital Epidemiology, University Hospital Geneva, University of Geneva, Geneva, Switzerland Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St Gallen, Switzerland Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland and Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland
    J Acquir Immune Defic Syndr 64:472-8. 2013
    ..The authors investigated the association between self-reported alcohol consumption and HIV surrogate markers in both treated and untreated individuals...
  13. ncbi request reprint Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection
    Handan Wand
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
    AIDS 21:2445-53. 2007
    ..Metabolic syndrome (MS) identifies individuals at risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). Little is known about MS and its consequences following initiation of antiretroviral therapy (ART)...
  14. pmc The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular Events
    Gilles Wandeler
    Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland Division of Infectious Diseases and Hospital Epidemiology, University Hospital, University of Zurich, University Hospital Zurich, Zurich, Switzerland Cantonal Hospital Aarau, Aarau, Switzerland University Hospital Geneva, Geneva, Switzerland University Hospital Lausanne, Lausanne, Switzerland University Hospital Basel, Basel, Switzerland Cantonal Hospital, St Gallen, Switzerland and Regional Hospital, Lugano, Switzerland
    J Acquir Immune Defic Syndr 71:302-9. 2016
    ..Whether the same holds true for HIV-infected individuals has not been evaluated in detail...
  15. doi request reprint Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS)
    Reto Nuesch
    Division of Infectious Diseases, Hirslanden Klinik St Anna, Lucerne, Switzerland Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland Division of Infectious Diseases, Regional Hospital of Lugano, Lugano, Switzerland Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland Division of Infectious Diseases, University Hospital Lausanne, Lausanne, Switzerland Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital of St Gallen, St Gallen, Switzerland Division of Infectious Diseases, University Hospital Bern and University of Bern, Bern, Switzerland and Division of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland
    J Acquir Immune Defic Syndr 62:396-404. 2013
    ..We modeled blood pressure over time and the risk of cardiovascular events in hypertensive HIV-infected individuals...
  16. ncbi request reprint A new era of antiretroviral drug toxicity
    Alexandra Calmy
    Geneva University Hospital, HIV Unit, Geneva, Switzerland
    Antivir Ther 14:165-79. 2009
    ..We review life-threatening adverse events, adverse events of new investigational or recently marketed drugs, adverse events with a genetic component and tissue-specific adverse events of fat, heart, bone, kidney and liver...
  17. doi request reprint Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis
    Nathan Ford
    Medecins Sans Frontieres, Geneva, Switzerland
    AIDS 27:1135-43. 2013
    ..We conducted a systematic review and meta-analysis of severe adverse events in HIV-positive women who initiated NVP while pregnant...
  18. doi request reprint Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections
    Juan Ambrosioni
    Laboratory of Virology, Department of Genetics and Laboratory Medicine, University Hospital, Geneva, Switzerland
    AIDS 26:2079-86. 2012
    ..To evaluate HIV-1 transmission trends and the impact of highly active antiretroviral therapy (HAART) on newly diagnosed HIV infections in Geneva, Switzerland...
  19. pmc HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons
    Florian Bihl
    Cantonal Hepatobiliary Unit, Ente Ospedaliera Cantonale, Ospedale San Giovanni Bellinzona, Switzerland and Gastroenterology and Hepatology Service, University Hospital of Geneva, Geneva, Switzerland
    BMC Gastroenterol 15:79. 2015
    ..Tenofovir disoproxil fumarate (TDF) plays a pivotal role in antiretroviral therapy (ART) of HIV/HBV-coinfected patients. The influence of HBV genotypes on the response to antiviral drugs, particularly TDF, is poorly understood...
  20. doi request reprint Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review
    Nathan Ford
    Department of HIV AIDS, World Health Organization, Geneva, Switzerland
    Clin Infect Dis 60:S170-6. 2015
    ..We undertook a systematic review to assess the safety and efficacy of antiretroviral options for PEP to inform the World Health Organization guideline revision process...
  21. doi request reprint The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV
    Philipp Kohler
    aDivision of Infectious Diseases and Infection Control, Cantonal Hospital St Gallen bDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich cCommunicable Diseases Division, Federal Office of Public Health FOPH, Bern, Switzerland dDepartment of Social and Environmental Health Research, London School of Hygiene and Tropical Medicine, UK eDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Lausanne fUniversity Clinic of Infectious Diseases, University Hospital Bern gHIV Unit, Geneva University Hospital, Geneva hDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel iOspedale Regionale, Lugano, Switzerland
    AIDS 29:2509-15. 2015
    ..To describe the HIV care cascade for Switzerland in the year 2012...
  22. doi request reprint Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials
    Nathan Ford
    Department of HIV AIDS, World Health Organization, Geneva, Switzerland Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom Chelsea and Westminster NHS Hospital Foundation Trust and St Stephens AIDS Trust, London, United Kingdom Lawson Unit, Royal Sussex County Hospital, Brighton, United Kingdom and HIV AIDS Unit, Infectious Disease Service, Geneva University Hospital, Geneva, Switzerland
    J Acquir Immune Defic Syndr 69:422-9. 2015
    ..Efavirenz (EFV) is widely used for the treatment of antiretroviral-naive HIV-positive individuals, but there are concerns about the risk of adverse neuropsychiatric events. We systematically reviewed the safety of EFV in first-line therapy...
  23. doi request reprint Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis
    Nathan Ford
    aDepartment of HIV AIDS, World Health Organization Geneva, Switzerland bDepartment of Infectious Disease Epidemiology, Imperial College London, London, UK cStanford Prevention Research Center, Stanford University, Stanford, California, USA dHIV AIDS Unit, Infectious Disease Service, Geneva University Hospital, Geneva, Switzerland
    AIDS 28:2721-7. 2014
    ..We evaluated variations in completion rates for HIV postexposure prophylaxis (PEP) according to the exposure type (occupational, nonoccupational, and sexual assault), patient, and programme characteristics...
  24. doi request reprint Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis
    Nathan Ford
    aHIV Department, World Health Organization, Geneva, Switzerland bEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Rockville, Maryland, USA cDepartment of Infectious Disease Epidemiology, Imperial College London, London, UK dHIV AIDS Unit, Infectious Disease Service, Geneva University Hospital eMédecins Sans Frontières, Geneva, Switzerland
    AIDS 28:S123-31. 2014
    ..The objective of this review is to update evidence on efavirenz safety in HIV-infected pregnant women to inform revision of the 2013 WHO guidelines for antiretroviral therapy in low and middle-income countries...
  25. doi request reprint Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study
    Jim Young
    Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland Analysis Group Inc, Montreal, QC, Canada Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada Department of Medicine, Royal Victoria Hospital, McGill University Health Centre, Montreal, QC, Canada Division of Infectious Diseases, Regional Hospital of Lugano, Lugano, Switzerland Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St Gallen, Switzerland Division of Infectious Diseases, University Hospital Geneva, Geneva, Switzerland Division of Infectious Diseases, University Hospital Lausanne, Lausanne, Switzerland Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland Division of Infectious Diseases and Hospital Epidemiology, University Hospital and University of Zurich, Zurich, Switzerland and Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    J Acquir Immune Defic Syndr 69:413-21. 2015
    ..There is concern that this association arises because of a channeling bias. Even if exposure is a risk, it is not clear how that risk changes as exposure cumulates...
  26. doi request reprint Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV
    Roger D Kouyos
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland, Institute of Medical Virology, University of Zurich, Zurich, Switzerland, Laboratory of Virology, University Hospital Geneva, Geneva, Switzerland, Division of Immunology and Allergy, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland, Department Biomedicine, University of Basel, Basel, Switzerland, Division of Infectious Diseases, Geneva University Hospital, Geneva, Division of Immunology, University Hospital Lausanne, Lausanne, Switzerland, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Division of Infectious Diseases, Cantonal Hospital St Gallen, St Gallen, Switzerland and Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland
    Int J Epidemiol 43:887-96. 2014
    ..HCV coinfection remains a major cause of morbidity and mortality among HIV-infected individuals and its incidence has increased dramatically in HIV-infected men who have sex with men(MSM)...
  27. pmc Preferred antiretroviral drugs for the next decade of scale up
    Isabelle Andrieux-Meyer
    Medecins Sans Frontieres, Geneva, Switzerland
    J Int AIDS Soc 15:17986. 2012
    ..This commentary reviews recommendations made in an expert consultation on treatment scale up in resource-limited settings...
  28. doi request reprint Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis
    Nathan Ford
    Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa
    AIDS 25:2301-4. 2011
    ..85 (95% CI 0.61-1.20). One neural tube defect was observed (myelomeningocele), giving an incidence of 0.07% (95% CI 0.002-0.39)...
  29. doi request reprint How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals
    Jens Van Roey
    Medecins Sans Frontieres, Campaign for Access to Essential Medecins, Rue de Lausanne 78, 1211 Geneva, Switzerland
    Drug Discov Today 13:601-5. 2008
    ..Key research questions relevant for developing countries need to be answered early in the drug development process to ensure maximum benefit for the majority...
  30. doi request reprint Health perceptions of African HIV-infected patients and their physicians
    Melissa I Dominicé Dao
    Geneva University Hospitals, Community Medicine and Primary Care Department, Geneva, Switzerland
    Patient Educ Couns 80:185-90. 2010
    ....
  31. doi request reprint Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemia
    Tristan Ferry
    Geneva University Hospital, Geneva, Switzerland
    Clin Infect Dis 50:115-8. 2010
    ..Sixteen patients had circulating DNA, with no apparent clinical impact. Erythrovirus-associated anemia is an extremely rare event in HIV-infected patients...
  32. doi request reprint Hepatitis C Virus Awareness Among Men Who Have Sex With Men in Southwest Switzerland
    Olivier Clerc
    From the Infectious Diseases Service and Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland and HIV Unit, Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland
    Sex Transm Dis 43:44-8. 2016
    ..We aimed to evaluate transmission risk factors, awareness, and seroprevalence of HCV among MSM in southwest Switzerland...
  33. doi request reprint Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study
    Laura Ciaffi
    HIV Unit, Department of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland
    Eur J Clin Invest 45:720-30. 2015
    ..In dyslipidaemic patients with HIV infection, we assessed the efficacy of replacing boosted protease inhibitor (bPI) or efavirenz (EFV) by etravirine (ETR) as an alternative to statin therapy...
  34. doi request reprint Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality
    Tracy R Glass
    aBasel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel bSwiss Tropical and Public Health Institute cUniversity of Basel, Basel, Switzerland dDepartment of Social Medicine, University of Bristol, Bristol, UK eCommunity pharmacy, Department of Ambulatory Care and Community Medicine, University of Lausanne fCommunity pharmacy, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Lausanne gInstitute of Nursing Science, University of Basel, Basel hDivision of Infectious Diseases, Kantonsspital St Gallen, St Gallen iDepartment of Infectious Diseases, Bern University Hospital and University of Bern, Bern jDivision of Infectious Diseases and Hospital Epidemiology University Hospital Zurich and University of Zurich, Zurich kDivision of Infectious Diseases, Ospedale Civico Lugano, Lugano lDivision of Infectious Diseases, University Hospital Geneva, Geneva mSwiss HIV Cohort Data Center, University Institute of Social and Preventive Medicine Lausanne, Lausanne nDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    AIDS 29:2195-200. 2015
    ..To determine the effect of nonadherence to antiretroviral therapy (ART) on virologic failure and mortality in naive individuals starting ART...
  35. pmc Driving a decade of change: HIV/AIDS, patents and access to medicines for all
    Ellen t Hoen
    Medicines Patent Pool Initiative, UNITAID Secretariat, Geneva, Switzerland
    J Int AIDS Soc 14:15. 2011
    ..Governments must live up to their obligations to protect access to medicines as a fundamental component of the human right to health...
  36. pmc Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings
    Janice Soo Fern Lee
    Medecins Sans Frontieres, Geneva University Hospital, Geneva, Switzerland
    HIV AIDS (Auckl) 4:5-15. 2012
    ..Clinical trials addressing specific challenges encountered in resources-limited settings should be encouraged...
  37. pmc HIV treatment for prevention
    Juan Ambrosioni
    HIV Unit, Department of Infectious Diseases, University of Geneva Hospitals, Geneva, Switzerland
    J Int AIDS Soc 14:28. 2011
    ..This will lead to a decrease in HIV transmission while "test-and-treat" is fully explored in prospective clinical trials...
  38. ncbi request reprint Evidence on the Protective Role of High-Density Lipoprotein (HDL) in HIV-Infected Individuals
    Alexandra Calmy
    Division of Infectious Diseases, Department of Medical Specialties, Geneva University Hospital, 4 rue Gabrielle Perret Gentil, 1205 Geneva, Switzerland
    Curr Vasc Pharmacol 13:167-72. 2015
    ..The present review will discuss the promising role of HDL in HIV-related cardiovascular pathophysiology and update novelties from clinical studies targeting HDL increase in HIV patients. ..
  39. pmc Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine
    Claire Anne Siegrist
    Department of Pathology Immunology and Paediatrics, Centre for Vaccinology, University Hospitals of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland
    PLoS ONE 7:e40428. 2012
    ..Memory responses require immune competence. We assessed the influence of priming with AS03-adjuvanted pandemic vaccine (Pandemrix®) on memory responses of HIV patients, kidney recipients (SOT) and healthy controls (HC)...
  40. pmc Squamous cell carcinoma of the anus-an opportunistic cancer in HIV-positive male homosexuals
    Pascal Gervaz
    Department of Surgery, Geneva University Hospital and Medical School, 1211 Geneve, Switzerland
    World J Gastroenterol 17:2987-91. 2011
    ..In addition, definitive eradication of oncogenic HPVs within the anogenital mucosa of high-risk individuals might require a proactive approach with repeated vaccination...
  41. pmc Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings
    Nathan Ford
    Medecins Sans Frontieres, Geneva, Switzerland
    HIV AIDS (Auckl) 3:35-44. 2011
    ..These characteristics make rilpivirine an attractive drug for resource-limited settings. Future research should assess the potential to improve robustness and assess the clinical significance of interaction with antituberculosis drugs...
  42. pmc The first decade of antiretroviral therapy in Africa
    Nathan Ford
    Medecins Sans Frontieres, Geneva, Switzerland
    Global Health 7:33. 2011
    ....
  43. ncbi request reprint HIV drug resistance
    Alexandra Calmy
    N Engl J Med 350:2720-1. 2004
  44. ncbi request reprint Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy
    Jean Philippe Zuber
    University and Cantonal Hospitals of Zurich, Zurich, Switzerland
    Clin Infect Dis 38:1178-85. 2004
    ..7 years. HAART significantly decreased mortality due to PAHRH as well as other causes. This study suggests a beneficial effect of combination ART in patients with PAHRH...
  45. ncbi request reprint Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine
    Milos Opravil
    AIDS 18:2213-5. 2004
  46. ncbi request reprint Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon
    Anke Bourgeois
    Institut de Recherche pour le Développement and Department of International Health, University of Montpellier UMR 145, Montpellier, France
    Antivir Ther 10:335-41. 2005
    ..To assess the effectiveness of generic anti-retroviral drugs in terms of survival and virological and immunological responses, as well as their tolerability and the emergence of viral resistance...
  47. ncbi request reprint Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans Frontières
    Jean Michel Tassie
    Epicentre, Paris, France
    AIDS 17:1995-7. 2003
    ..At 6 months, outcomes were similar to those observed in western countries, and the probability of remaining on treatment was 94%. The challenge now is to extend access to HAART to the millions in urgent need...
  48. ncbi request reprint Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial
    Christian Laurent
    Institut de Recherche pour le Développement and Department of International Health, University of Montpellier UMR 145, Montpellier, France
    Lancet 364:29-34. 2004
    ..We aimed to assess these issues for one of the most frequently prescribed treatments in Africa, a generic fixed-dose combination of nevirapine, stavudine, and lamivudine...
  49. ncbi request reprint Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort
    Alexandra Calmy
    MSF, Campaign for Access to Essential Medicines, 78 rue de Lausanne, 1205 Geneva, Switzerland
    AIDS 20:1163-9. 2006
    ..The use fixed-dose combination (FDC) is a critical tool in improving HAART. Studies on the effectiveness of combined lamivudine, stavudine and nevirapine (3TC/d4T/NVP) are scarce...
  50. doi request reprint Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières
    Mar Pujades-Rodriguez
    Epicentre, Paris, France
    AIDS 22:1305-12. 2008
    ..To describe the use of second-line protease-inhibitor regimens in Médecins Sans Frontières HIV programmes, and determine switch rates, clinical outcomes, and factors associated with survival...
  51. doi request reprint Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon
    Charles Kouanfack
    Central Hospital, Yaounde, Cameroon
    J Acquir Immune Defic Syndr 48:216-9. 2008
    ..To compare adherence to antiretroviral therapy using drug level monitoring and self-report and to explore the relation between these 2 methods and viral load measurements...
  52. ncbi request reprint Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up
    Alexandra Calmy
    AIDS 18:2353-60. 2004
  53. ncbi request reprint Treating HIV in the developing world: getting ahead of the drug development curve
    Nathan Ford
    Drug Discov Today 12:1-3. 2007
  54. doi request reprint Monitoring of antiretroviral therapy in low-resource settings
    Stephen D Lawn
    Lancet 372:287-8; author reply 289. 2008
  55. ncbi request reprint Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine
    Christian Laurent
    IRD, UMR 145 IRD University of Montpellier 1, Montpellier, France
    AIDS 21:768-71. 2007
    ..Virological effectiveness appeared to wane somewhat during the second year of treatment, however, and plasma nevirapine concentrations were relatively high...
  56. ncbi request reprint First-line and second-line antiretroviral therapy
    Alexandra Calmy
    Lancet 364:329; author reply 330. 2004
  57. pmc Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006
    Florence Damond
    APHP, Hopital Bichat Claude Bernard, Laboratoire de Virologie, Paris, 75018 France
    J Clin Microbiol 46:2088-91. 2008
    ..Quantification varied between laboratories, and international standardization of quantification assays is strongly needed...
  58. doi request reprint Initial treatment for HIV infection--an embarrassment of riches
    Bernard Hirschel
    N Engl J Med 358:2170-2. 2008
  59. ncbi request reprint (The Lancet)red: a missed opportunity
    Alexandra Calmy
    Lancet 368:1063. 2006